NO20082434L - Materialer og fremgangsmater for behandling av kroniske fibrotiske sykdommer - Google Patents
Materialer og fremgangsmater for behandling av kroniske fibrotiske sykdommerInfo
- Publication number
- NO20082434L NO20082434L NO20082434A NO20082434A NO20082434L NO 20082434 L NO20082434 L NO 20082434L NO 20082434 A NO20082434 A NO 20082434A NO 20082434 A NO20082434 A NO 20082434A NO 20082434 L NO20082434 L NO 20082434L
- Authority
- NO
- Norway
- Prior art keywords
- treatment
- methods
- materials
- fibrotic diseases
- chronic fibrotic
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 230000003176 fibrotic effect Effects 0.000 title abstract 2
- 230000001684 chronic effect Effects 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 206010016654 Fibrosis Diseases 0.000 abstract 2
- 230000004761 fibrosis Effects 0.000 abstract 2
- 102100036842 C-C motif chemokine 19 Human genes 0.000 abstract 1
- 102100036846 C-C motif chemokine 21 Human genes 0.000 abstract 1
- 101000713106 Homo sapiens C-C motif chemokine 19 Proteins 0.000 abstract 1
- 101000713085 Homo sapiens C-C motif chemokine 21 Proteins 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 230000003902 lesion Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A61P33/12—Schistosomicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
- C12N5/16—Animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2525/00—Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
- C12Q2525/10—Modifications characterised by
- C12Q2525/207—Modifications characterised by siRNA, miRNA
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Cardiology (AREA)
- Physics & Mathematics (AREA)
- Ophthalmology & Optometry (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US75364705P | 2005-12-23 | 2005-12-23 | |
PCT/US2006/048282 WO2007075592A2 (fr) | 2005-12-23 | 2006-12-19 | Substances et procedes de traitement de fibroses chroniques |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20082434L true NO20082434L (no) | 2008-08-26 |
Family
ID=38218516
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20082434A NO20082434L (no) | 2005-12-23 | 2008-05-27 | Materialer og fremgangsmater for behandling av kroniske fibrotiske sykdommer |
Country Status (16)
Country | Link |
---|---|
US (1) | US8795668B2 (fr) |
EP (1) | EP1963492A4 (fr) |
JP (1) | JP2009528977A (fr) |
KR (1) | KR20080081069A (fr) |
CN (1) | CN101351545A (fr) |
BR (1) | BRPI0619638A2 (fr) |
CA (1) | CA2633641A1 (fr) |
MA (1) | MA31060B1 (fr) |
MX (1) | MX2008008238A (fr) |
NO (1) | NO20082434L (fr) |
NZ (1) | NZ568991A (fr) |
RU (1) | RU2446825C2 (fr) |
TN (1) | TNSN08277A1 (fr) |
TW (1) | TW200733974A (fr) |
WO (1) | WO2007075592A2 (fr) |
ZA (1) | ZA200804294B (fr) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5337405B2 (ja) | 2007-09-17 | 2013-11-06 | ザ・ホスピタル・フォー・シック・チルドレン | ゴーシェ病の治療方法 |
WO2009121031A1 (fr) * | 2008-03-27 | 2009-10-01 | Vascular Biosciences, Inc. | Procédé d'identification de nouveaux candidats thérapeutiques via l'analyse d'expression génique dans les maladies d'origine vasculaire |
WO2010062640A1 (fr) * | 2008-10-28 | 2010-06-03 | Gilead Colorado, Inc. | Procédés de traitement d'une fibrose pulmonaire idiopathique et de complications associées |
JP5801202B2 (ja) * | 2009-09-29 | 2015-10-28 | 学校法人慶應義塾 | 抗腫瘍剤およびそのスクリーニング方法 |
WO2011047287A1 (fr) * | 2009-10-15 | 2011-04-21 | Immuneregen Biosciences, Inc. | Méthodes de traitement de maladies pulmonaires inflammatoires et fibrotiques avec des analogues de la substance p |
WO2011080050A2 (fr) * | 2009-12-11 | 2011-07-07 | Novartis Ag | Molécules de liaison |
EP2623592B1 (fr) | 2010-09-28 | 2019-05-15 | NB Health Laboratory Co. Ltd. | Anticorps anti-ccr7 humain, hybridome, composition thérapeutique et vecteur à anticorps immobilisé |
KR101697396B1 (ko) * | 2011-02-02 | 2017-01-17 | 엑스칼리아드 파마슈티컬즈, 인코포레이티드 | 결합 조직 성장 인자(ctgf)를 표적으로 하는 안티센스 화합물을 사용하여 켈로이드 또는 비후성 흉터를 치료하는 방법 |
GB201118840D0 (en) * | 2011-11-01 | 2011-12-14 | Univ Sheffield | Pulmonary hypertension II |
CN102526114A (zh) * | 2011-12-27 | 2012-07-04 | 苏州人本药业有限公司 | 物理改性后的眼镜蛇蛇毒在制备治疗肺纤维化药物中的用途 |
WO2015147335A1 (fr) * | 2014-03-27 | 2015-10-01 | 国立大学法人大阪大学 | Diagnostic et traitement du paludisme cérébral |
US20170035703A1 (en) * | 2015-10-29 | 2017-02-09 | Hans M. Albertsen | Method of Treating Adhesion by Altering an Epithelial to Mesenchymal Transition |
EP3604529A4 (fr) * | 2017-03-29 | 2021-01-06 | Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences | Microarn et utilisations de celui-ci dans la prévention et/ou le traitement d'un signe et/ou d'un syndrome médical de fibroplasie |
WO2018195392A1 (fr) * | 2017-04-20 | 2018-10-25 | Thomas Jefferson University | Le tramétinib empêche une transition mésothélio-mésenchymateuse et améliore l'adhérence abdominale et la formation de fibrose pulmonaire |
EP3724219A4 (fr) * | 2017-12-14 | 2021-09-08 | The University of Chicago | Traitement de la fibrose par des macrophages génétiquement modifiés |
CN108524912A (zh) * | 2018-04-26 | 2018-09-14 | 高常青 | 一种肺纤维化动物模型的构建方法 |
RU2735054C1 (ru) * | 2020-02-27 | 2020-10-27 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр кардиологии" Министерства здравоохранения Российской Федерации | Способ профилактики развития реперфузионного поражения ткани легкого с помощью неинвазивной искусственной вентиляции лёгких постоянным положительным давлением у неоперабельных больных с хронической тромбоэмболической легочной гипертензией после транслюминальной баллонной ангиопластики легочной артерии |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL95031A (en) * | 1989-07-18 | 2007-03-08 | Amgen Inc | A method of producing a recombinant human necrotic factor absorber |
KR100234520B1 (ko) * | 1991-01-18 | 1999-12-15 | 그레고리 아보트 | 종양괴사인자 매개병 치료용 의약품 조성물 |
US6495129B1 (en) * | 1994-03-08 | 2002-12-17 | Human Genome Sciences, Inc. | Methods of inhibiting hematopoietic stem cells using human myeloid progenitor inhibitory factor-1 (MPIF-1) (Ckbeta-8/MIP-3) |
ATE290080T1 (de) * | 1994-08-23 | 2005-03-15 | Human Genome Sciences Inc | Menschliches beta-9 chemokin |
US6139832A (en) * | 1995-02-08 | 2000-10-31 | Human Genome Sciences, Inc. | Leukocyte adhesion inhibitor-1 (LAI-1) Polypeptides |
ATE410179T1 (de) * | 1997-08-08 | 2008-10-15 | Univ California | Behandlung von leberfibrose mit anti-alpha v beta 6 integrin antikörpern |
US20020168358A1 (en) * | 2001-04-30 | 2002-11-14 | Gladue Ronald P. | Treatment of T-cell mediated diseases |
EP1404180A4 (fr) * | 2001-06-04 | 2004-10-20 | Cytokine Pharmasciences Inc | Voie de differenciation de fibrocytes sanguins peripheriques et migration vers des sites leses |
TWI430810B (zh) * | 2002-07-19 | 2014-03-21 | Abbott Lab S A | TNFα相關病症之治療 |
DK1596880T3 (da) * | 2002-12-23 | 2011-06-14 | Univ Rice William M | Fremgangsmåder og sammensætninger til undertrykkelse af fibrocytdifferentiering |
MXPA05007466A (es) * | 2003-01-09 | 2006-03-08 | Arizeke Pharmaceuticals Inc | Metodos para el tratamiento de enfermedades pulmonares. |
US20050008639A1 (en) * | 2003-02-14 | 2005-01-13 | Chervonsky Alexander V. | Methods of modulating homing of T cell by interruption of chemokine/chemokine receptor signaling |
-
2006
- 2006-12-18 US US11/641,465 patent/US8795668B2/en not_active Expired - Fee Related
- 2006-12-19 WO PCT/US2006/048282 patent/WO2007075592A2/fr active Application Filing
- 2006-12-19 MX MX2008008238A patent/MX2008008238A/es not_active Application Discontinuation
- 2006-12-19 EP EP06848920A patent/EP1963492A4/fr not_active Withdrawn
- 2006-12-19 CA CA002633641A patent/CA2633641A1/fr not_active Abandoned
- 2006-12-19 NZ NZ568991A patent/NZ568991A/en not_active IP Right Cessation
- 2006-12-19 BR BRPI0619638-1A patent/BRPI0619638A2/pt not_active IP Right Cessation
- 2006-12-19 ZA ZA200804294A patent/ZA200804294B/xx unknown
- 2006-12-19 KR KR1020087018174A patent/KR20080081069A/ko not_active Application Discontinuation
- 2006-12-19 RU RU2008130410/15A patent/RU2446825C2/ru not_active IP Right Cessation
- 2006-12-19 CN CNA2006800483424A patent/CN101351545A/zh active Pending
- 2006-12-19 JP JP2008547405A patent/JP2009528977A/ja active Pending
- 2006-12-22 TW TW095148606A patent/TW200733974A/zh unknown
-
2008
- 2008-05-27 NO NO20082434A patent/NO20082434L/no not_active Application Discontinuation
- 2008-06-20 TN TNP2008000277A patent/TNSN08277A1/en unknown
- 2008-07-18 MA MA31135A patent/MA31060B1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
WO2007075592A3 (fr) | 2008-06-12 |
RU2008130410A (ru) | 2010-01-27 |
US8795668B2 (en) | 2014-08-05 |
MX2008008238A (es) | 2009-01-07 |
CN101351545A (zh) | 2009-01-21 |
US20070172856A1 (en) | 2007-07-26 |
WO2007075592A9 (fr) | 2007-09-13 |
TNSN08277A1 (en) | 2009-10-30 |
WO2007075592A2 (fr) | 2007-07-05 |
EP1963492A4 (fr) | 2010-06-09 |
MA31060B1 (fr) | 2010-01-04 |
ZA200804294B (en) | 2009-07-29 |
KR20080081069A (ko) | 2008-09-05 |
RU2446825C2 (ru) | 2012-04-10 |
JP2009528977A (ja) | 2009-08-13 |
BRPI0619638A2 (pt) | 2011-10-04 |
EP1963492A2 (fr) | 2008-09-03 |
NZ568991A (en) | 2012-04-27 |
TW200733974A (en) | 2007-09-16 |
CA2633641A1 (fr) | 2007-07-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20082434L (no) | Materialer og fremgangsmater for behandling av kroniske fibrotiske sykdommer | |
SG151327A1 (en) | Deazapurines useful as inhibitors of janus kinases | |
SG170828A1 (en) | Deazapurines useful as inhibitors of janus kinases | |
EP2537849A3 (fr) | Azaindoles utiles en tant qu'inhibiteurs des kinases Janus | |
WO2006003388A3 (fr) | Compositions et procedes pour le traitement de troubles inflammatoires | |
WO2008116139A3 (fr) | Composés utiles en tant qu'inhibiteurs des kinases de janus | |
WO2007090068A3 (fr) | Composes de cyanoisoquinoleine et procedes d'utilisation de ceux-ci | |
WO2010068794A3 (fr) | Inhibiteurs de hif et leurs applications | |
WO2007076161A3 (fr) | Composés ayant une activité thérapeutique | |
EP2018377A4 (fr) | Dérivés de 2-pyrazinone destinés au traitement d'une maladie ou d'un état dans lequel l'inhibition de l'élastase neutrophile humaine a un effet bénéfique | |
WO2005112970A3 (fr) | Utilisation de gelsoline pour le traitement d'infections | |
WO2006138609A3 (fr) | Traitement d'etats inflammatoires | |
WO2007114903A3 (fr) | Traitements à la citrulline | |
IL193080A0 (en) | Methods, compositions, and kits for the treatment of musculoskeletal disorders and symptoms associated therewith | |
WO2007117557A3 (fr) | Diaminopropanols inhibiteurs de rénine | |
WO2008077092A8 (fr) | Effets combinés de topiramate/ondansetrone sur la consommation d'alcool | |
WO2010077339A3 (fr) | Effecteurs de la β-arrestine, compositions en contenant et leurs procédés d'utilisation | |
WO2008034796A3 (fr) | Triazoles thérapeutiquement actives et leur utilisation | |
WO2006122123A3 (fr) | Procedes de soulagement de troubles et de leurs douleurs associees | |
MXPA05010400A (es) | Composicion para evitar o tratar una enfermedad alergica utilizando extracto de arroz negro y su uso terapeutico. | |
WO2007117560A3 (fr) | Pipéridine et morpholine inhibiteurs de la rénine | |
WO2007041614A3 (fr) | Inhibiteurs de vegf a action prolongee et leurs methodes d'utilisation | |
WO2007084651A3 (fr) | Procedes et kits de traitement de maladies immunitaires inflammatoires chroniques par administration d'un inhibiteur de proteasome et d'un agoniste de recepteur d'interleukine 2 | |
WO2006079068A3 (fr) | Compositions et methodes permettant d'etudier et de traiter des maladies et des troubles inflammatoires | |
WO2009143064A3 (fr) | Extraits de son de riz pour traiter l'inflammation et procédés d'utilisation de ceux-ci |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |